NEW YORK, April 11, 2017 /PRNewswire/ --
Stock-Callers.com today observes the following Generic Drugs equities: ZynerbaPharmaceuticals Inc. (NASDAQ: ZYNE), Patheon N.V. (NYSE: PTHN), SCYNEXIS Inc. (NASDAQ: SCYX), and Flexion Therapeutics Inc. (NASDAQ: FLXN). According to a report on IBISWorld, the Generic Pharmaceutical Manufacturing industry exhibits a low level of
On Monday, shares of Devon, Pennsylvania headquartered Zynerba Pharmaceuticals Inc. recorded a trading volume of 1.71 million shares, which was above their three months average volume of 464,070 shares. The stock ended at $24.78, soaring 12.18% from the last trading session. The Company's shares have surged 22.25% in the last one month, 37.06% over the previous three months, and 58.95% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 22.11% and 74.90%, respectively. Furthermore, shares of Zynerba Pharma, which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery, have a Relative Strength Index (RSI) of 72.06.
On March 27th, 2017, Zynerba Pharma reported financial results for Q4 and year ended December 31st, 2016, and provided an overview of recent operational highlights. As of December 31, 2016, cash and cash equivalents totaled $31.0 million, while for Q4 2016, R&D expenses were $4.9 million, and net loss was $6.9 million. For the year ended December 31st, 2016, R&D expenses were $16.8 million and net loss was $23.4 million.
On March 28th, 2017, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $22 a share to $30 a share. Access our complete research report on ZYNE for free at:
Amsterdam, the Netherlands-based Patheon N.V.'s stock finished yesterday's session 1.42% lower at $26.30 with a total trading volume of 319,959 shares. The Company's shares are trading below their 200-day moving average by 6.34%. Shares of the Company, which provides outsourced pharmaceutical development and manufacturing services, have an RSI of 34.46.
On March 17th, 2017, research firm Robert W. Baird downgraded the Company's stock rating from 'Outperform' to 'Neutral' while revising its previous target price from $34 a share to $28 a share.
On March 30th, 2017, Patheon announced that it has been cited once again as capturing the most outsourced new drug approvals (NDA) in the US than any other contract manufacturing organization in 2016. Key findings of the report include the Company receiving 17 out of 55 (30%) of all outsourced NDA approvals in 2016, and 112 new molecular entity (NME) and non-NME NDA approvals. The complimentary research report on PTHN can be downloaded at:
At the close of trading on Monday, shares in Jersey City, New Jersey headquartered SCYNEXIS Inc. rose 2.30%, ending the day at $2.67 with a total trading volume of 265,549 shares. The stock is trading 11.45% below its 50-day moving average. Shares of the Company, which develops and commercializes novel anti-infectives to address unmet therapeutic needs, have an RSI of 43.80.
On March 13th, 2017, SCYNEXIS reported financial results for the year ended December 31st, 2016, and provided an update on recent operational and clinical developments. For the full year 2016, cash and cash equivalents and short-term investments totaled $58.6 million; R&D expenses were $20.1 million; selling, general, and administrative expenses were $8.0 million; and loss from operations was $27.8 million. Register for free on Stock-Callers.com and get access to the latest PDF format report on SCYX at:
Burlington, Massachusetts headquartered Flexion Therapeutics Inc.'s shares ended the day 0.76% higher at $26.62 with a total trading volume of 276,154 shares. The stock has surged 28.41% in the last month, 34.65% over the previous three months, and 39.96% on an YTD basis. The Company's shares are trading 23.63% above their 50-day moving average and 41.06% above their 200-day moving average. Additionally, shares of Flexion Therapeutics, which focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions, have an RSI of 62.12.
On April 07th, 2017, Flexion Therapeutics announced that Yamo Deniz, MD, has been named Chief Medical Officer (CMO). This appointment strengthens the Company's leadership with an industry veteran who brings extensive experience leading medical and clinical development teams at major biotechnology and pharmaceutical companies. With the addition of Dr. Deniz, Neil Bodick, MD, PhD, co-founder of Flexion, will transition from his position as CMO and assume the role of Chief Scientific Officer. Download your free research report on FLXN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Drug abuse is a negative social trend that pushes youth to drug addiction in the pretext of getting ...
Proper understanding of waste collection, segregation and management is required to reduce the ...
Leukoplakia refers to a painless, raised white patch in the mouth that does not go away on rubbing, ...View All